NIH Reporter #5U01CA275310-04

NCI Grant for Research on Synthetic Lethal Targeting of EBV-Positive Diffuse Large B Cell Lymphomas in HIV-Positive Individuals

This opportunity is a grant solicitation from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for research on synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in HIV-positive individuals. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - OEMs and Vendors: - No specific OEMs or vendors are named in this opportunity - Products/Services Requested: - Research services focused on synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas - Studies to include use of cell lines, xenografts, and patient-derived samples - Mechanistic investigation of the link between Epstein-Barr Virus (EBV), DNA repair pathways, and synthetic lethal therapies - Unique or Notable Requirements: - Research must address cancer, hematology, infectious diseases, lymphoma, HIV/AIDS, rare diseases, lymphatic research, and orphan drug development - No specific products, part numbers, or purchase quantities are listed - Applications must use the standard NIH grant application format - Estimated funding amount is $676,145

Description

This NIH grant opportunity supports research on the mechanistic link between Epstein-Barr Virus (EBV), DNA repair pathways, and synthetic lethal therapies in diffuse large B cell lymphomas among HIV-positive individuals. The project involves studies using cell lines, xenografts, and patient-derived samples to explore potential treatments. The funding amount is approximately $676,145, with a project duration from September 2022 to August 2027. The grant is issued by the National Cancer Institute (NCI), part of the NIH.

View original listing